Attovia Therapeutics, Inc. (NASDAQ:ATTO)
| Market Cap | $690.26M-31.1% |
| Revenue (ttm) | $1.44M |
| Net Income | -$78.87M |
| EPS | -$1.80 |
| Shares Out | 45.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 372,219 |
| Open | $15.40 |
| Previous Close | $15.58 |
| Day's Range | $14.80 - $15.46 |
| 52-Week Range | $12.94 - $28.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $45.33(+200.20%) |
| Earnings Date | Feb 8, 2027 |
About ATTO
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyAnalyst consensus
2 firms rating ATTO in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 8, 2027Earnings report
$ATTO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATTO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATTO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATTO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ATTO Revenue by Segment
| Clinical, manufacturing, and preclinical services | $15.06M | 76.52% |
| Personnel-related costs | $3.48M | 17.70% |
| Professional consulting services | $717.00K | 3.64% |
| Facilities and overhead costs | $420.00K | 2.13% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ATTO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATTO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ATTO
| VTIVanguard Morningstar Total Stock Market ETF | $6.80M |
| VXFVanguard Extended Market ETF | $2.98M |
| SCHASchwab U.S. Small-Cap ETF | $1.36M |
| VTWOVanguard Russell 2000 ETF | $270.41K |
| SCHBSchwab U.S. Broad Market ETF | $169.56K |
| VTWGVanguard Russell 2000 Growth ETF | $27.07K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ATTO’s recent data — informational, not investment advice
